Publications by authors named "Raymond Yurko"

Claim this Profile
R
Reversing cardiac hypertrophy and heart failure using a cardiac targeting peptide linked to miRNA106a.
Ming Lu, Siqi Cai, Kyle Korolowicz, Claire Deng, Kaan Taskintuna, Raymond B Yurko

Clin Transl Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Lung Cell-Penetrating Peptide Targets Alveolar Epithelial Type II Cells, Basal Cells, and Ionocytes.
Jin Wen, Gajalakshmi Singuru, Jeffrey Stiltner, Sanjay Mishra, Kyle S Feldman, Raymond Yurko

Pharmaceutics· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.
Kelsie M LaBarbera, Yvette I Sheline, Nicholas J Izzo, Carla M Yuede, Lora Waybright, Raymond Yurko

Transl Neurodegener· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Lung Targeting Cell Penetrating Peptides as Vectors for Delivery of Therapeutics.
Kayla McCandless, Sanjay Mishra, Jeffrey Stiltner, Kyle S Feldman, Hisato Yagi, Raymond Yurko

Res Sq· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease.
Gilbert M Rishton, Gary C Look, Zhi-Jie Ni, Jason Zhang, Yingcai Wang, Raymond Yurko

ACS Med Chem Lett· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
Nicholas J Izzo, Carla M Yuede, Kelsie M LaBarbera, Colleen S Limegrover, Courtney Rehak, Raymond Yurko

Alzheimers Dement· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery.
Kelsie Mozzoni LaBarbera, Colleen Limegrover, Courtney Rehak, Raymond Yurko, Nicholas John Izzo

J Neurosci Methods· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity.
Colleen S Limegrover, Harry LeVine, Nicholas J Izzo, Raymond Yurko, Kelsie Mozzoni

J Neurochem· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein.
Colleen S Limegrover, Raymond Yurko, Nicholas J Izzo, Kelsie M LaBarbera, Courtney Rehak

J Neurosci Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Targeting Peptide, a Novel Cardiac Vector: Studies in Bio-Distribution, Imaging Application, and Mechanism of Transduction.
Maliha Zahid, Kyle S Feldman, Gabriel Garcia-Borrero, Timothy N Feinstein, Nicholas Pogodzinski, Raymond Yurko

Biomolecules· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of a potential diagnostic biomarker for HIV infection from a random library of non-biological synthetic peptoid oligomers.
Tricia L Gearhart, Ronald C Montelaro, Mark E Schurdak, Chris D Pilcher, Charles R Rinaldo, Raymond Yurko

J Immunol Methods· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
Nicholas J Izzo, Agnes Staniszewski, Lillian To, Mauro Fa, Andrew F Teich, Raymond Yurko

PLoS One· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
Nicholas J Izzo, Jinbin Xu, Chenbo Zeng, Molly J Kirk, Kelsie Mozzoni, Raymond Yurko

PLoS One· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis